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Background/aim: To investigate the diagnostic value of bacterial artificial chromosome (BAC)-based array comparative genomic
hybridization (CGH) and chromosome analysis in prenatal diagnosis.
Materials and methods: This study included the chromosome analysis and BAC-based array CGH analysis of 140 amniocentesis
samples with prenatal diagnosis indications.
Results: Karyotype analysis showed trisomy 21 in 4 patients, trisomy 18 in 5 patients, monosomy X in 1 patient, and other anomalies
in 3 patients. The BAC-based array CGH analysis showed 4 patients with trisomy 21, 4 patients with trisomy 18, and 1 patient with
monosomy X as a numerical chromosome anomaly, while partial duplication was observed in chromosome 14 in 1 case as a structural
anomaly.
Conclusion: The array CGH is the most effective method available to complement cases where chromosome analysis, a gold standard
in prenatal diagnosis, proves to be insufficient. Considering the inherent limitations of both methods, complementary features should
be introduced in order to be able to give the most accurate data at the right time.
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1. Introduction
The main target of prenatal diagnosis is to diagnose
anomalies of the fetus in the early period and to enable the
parents to make their own decisions regarding the future
of the fetus within the framework of personal, social, and
ethical principles (1).
Prenatal diagnostic methods are classified as
noninvasive and invasive techniques. Ultrasonography
and biochemical tests performed on the mother’s blood
are the principal prenatal procedures. Invasive methods
such as amniocentesis or cordocentesis are used to gather
more information about fetal karyotype (2).
Fetal karyotyping is offered to pregnant women
with an elevated risk of carrying fetuses with
chromosomal anomalies due to advanced maternal age,
abnormal maternal serum screening results, abnormal
ultrasonography findings, or family history of chromosome
anomaly (3).
Chromosome analysis is the most common method
in prenatal diagnosis for genetic testing. This method
can detect all chromosome aneuploidies and structural
changes larger than approximately 5 Mb. Chromosome
* Correspondence: sssedaeren@yahoo.com

analysis is a procedure requiring culturing, with a longer
analysis process compared with molecular procedures.
Although all common aneuploidies can be detected with
this method, the long reporting process required the
development of diagnosis methods that could give quicker
results. The main procedures developed to address this
problem include fluorescent in situ hybridization (FISH),
quantitative polymerase chain reaction (QF-PCR), and
array-comparative genomic hybridization (aCGH)
methods. The use of the aCGH method, which allows for
detection at the whole-genome level, has become more
common in prenatal diagnosis (4–6).
The aCGH technique is a molecular cytogenetic
method originating from FISH, showing fluorescent color
differences acquired by binding test (patient) and reference
DNA samples stained with different fluorescent dyes (6).
The aCGH method is performed using the platforms
where relevant DNA series are spotted. Genomic
clones with large DNA fragments (bacterial artificial
chromosomes/P1 artificial chromosomes, BACs/PACs)
or DNA microarrays with smaller PCR products are
generated as targets for hybridization (7).
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It is possible to use aCGH, also called molecular
karyotyping, to screen genome-wide segmental genomic
copy number variations, such as deletions and duplications,
and also all aneuploidies (8,9).
This study aims to investigate the efficiency of
chromosome analysis in the diagnosis of genetic disorders
observed in the prenatal period and BAC-based aCGH
techniques, which have become more popular in recent
years, in prenatal diagnosis.
2. Materials and methods
2.1. Materials
In the Medical Genetics Laboratory of Kocaeli University
we performed both chromosome analysis and BAC aCGH
for 140 patients who applied to our clinic in between 2011
and 2012. All patients underwent pretest counseling.
This study was approved by the Local Research Ethics
Committee (KOU KAEK 2012/157).
2.2. Methods
2.2.1. Chromosome analysis
Chromosome analysis was performed according to
standard methods using cultured cells from 10 mL of
amniotic fluid. G-banded chromosomes were analyzed
and recorded according to the International System for
Human Cytogenetic Nomenclature (ISCN) 2008.
2.2.2. BAC-based aCGH
For aCGH, 5 mL of amniotic fluid was used. Amniocentesis
was done only once for each subject.
Genomic DNA was obtained using the Magna Pure
Compact Nucleic Acid Isolation Kit I (Roche Diagnostics
GmbH, Germany). Wave length absorbances of 260 and
280 nm were measured by spectrophotometer (NanoDrop,
ND-1000). gDNAs with an A260/A280 ratio between 1.7
and 2.0 were used. References and samples were labeled
with Cy5-dCTP and Cy3-dCTP using the Fluorescent
Labelling System (dCTP/BAC) Kit (BlueGnome Ltd.,
Cambridge, UK). After incubating for 16 to 20 h at 37
°C, samples were purified with AutoSeq G50 columns
(BlueGnome Ltd.). Human Cot-I DNA (BlueGnome
Ltd.) was added to avoid consecutive matches from
repetitive regions. Hybridization mixture was added and
denatured at 75 °C. Samples were loaded on Cytochip
Focus Constitutional V1.11 platforms (BlueGnome Ltd.)
and hybridized at 47 °C for 16–21 h. Finally, the platforms
were scanned (Agilent Microarray Scanner; Agilent
Technologies, Palo Alto, CA, USA) and analyzed by
BlueFuse Multi v2.1 software (BlueGnome Ltd.).
3. Results
The prenatal diagnosis indications of the study group
included advanced maternal age, high double-triple
screening test results, abnormal ultrasound findings,
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family history of an anomaly, family history of mental
retardation, and a family history of chromosome anomaly.
The distribution of cases by indications in the study group
is listed in Table 1.
Although the gestational age in cases of amniocentesis
varied between 12 and 28 weeks, the mean age was
calculated to be 20 weeks. The ages of mothers varied
between 18 and 46 years old, with the mean maternal age
being 32. Cell culture process performance was found to
be 97% (136/140) and the prenatal diagnostic rate was
99% (139/140) in the amniocentesis series. A specific
FISH method was conducted on chromosomes 13 and
21 as well as BAC-based aCGH in 3 of the cases where
no metaphases could be obtained for evaluation from cell
cultures. However, no analysis could be performed by
any method in 2 of the submitted samples, which were
contaminated with blood.
Chromosomal anomalies were detected in 14 (9%)
of 140 cases through results from applied cytogenetic
studies for prenatal diagnosis. Three of these chromosome
anomalies were structural anomalies, while 10 (76%) of
them were numerical ones. The most common anomalies
were karyotypes with trisomy 21 and trisomy 18 numerical
anomalies, while structural anomalies were observed at an
equal rate (7%).
Trisomy 21 was detected in 4 cases, trisomy 18 in 4
cases, and monosomy X in 1 case as a result of the BAC
array CGH analysis. BAC array and chromosome analysis
results are listed in Table 2.
4. Discussion
At least one prenatal diagnosis indication was found in
each of the cases in this study. An abnormal screening test
result (69%) was the most frequently observed indication,
with abnormal ultrasound findings (21%) ranking
second. Advanced maternal age ranked third at 11%.
Both incidence rate and incidence order differ among
genetic diagnosis centers throughout Turkey and in other
Table 1. Distribution of cases by indication.
Indication

%

n

Advanced maternal age

11.9

17

Abnormal serum screen

69

98

Abnormal ultrasound findings

21

30

Habitual abortion

0.7

1

Previous child with anomaly

1.4

2

Family history of mental retardation

0.7

1

Previous child with chromosome anomaly

0.7

1
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Table 2. Karyotype and BAC aCGH results of abnormal cases.
Indicator

Karyotype

BAC array CGH result

Abnormal serum screen

47,XX,+21[20]

Duplication of whole chr. 21

Advanced maternal age, abnormal ultrasound findings

47,XY,+18[30]

Duplication of whole chr. 18

Abnormal serum screen

Mosaic karyotype, 47,XY,+18[2]/46,XY[53]

Normal

Advanced maternal age

47,XX,rob(21;21)(q10;q10)[20]

Duplication of whole chr. 21

Abnormal serum screen

47,XY,+18[20]

Duplication of whole chr. 18

Abnormal serum screen

47,XY,+18[20]

Duplication of whole chr. 18

Abnormal serum screen

47,XY,+21[20]

Duplication of whole chr. 21

Abnormal serum screen

47,XX,+2[9]/46,XX[30]

Normal

Abnormal serum screen

46,XY,del(1)(q23)[2]/46,XY[98]

Normal

Abnormal serum screen

47,XY,+18[85]/46,XY[3]

Duplication of whole chr. 18

Abnormal serum screen, Abnormal ultrasound findings

47,XX,+18[20]

Duplication of whole chr. 18

Abnormal serum screen

46,XY,inv(4)(p13q21)[20]

Normal

Abnormal serum screen

47,XX,+21[20]

Duplication of whole chr. 21

Abnormal ultrasound findings

45,X[20]

Deletion of whole chr. X

Family history of mental retardation

47,XY,+mar[20]

Duplication of 14q11

countries. A study conducted in Turkey found, in contrast
to the findings of this study, high screening test results to
be 54.9%, advanced maternal age to be 20%, and abnormal
USG findings to be 16% (10). Tongsong et al., in a 1998
study, differed dramatically in their findings and reported
advanced maternal age to be 86% (11). It is striking that in
our study the acceptance rate of advanced maternal age as
an indication was reduced and that it was screening tests
and ultrasound findings that led to the prenatal diagnosis.
In their studies covering the subject matter, Dommergues
et al. concluded that amniocentesis should not be a routine
procedure in women with advanced maternal age, but that
it should be selectively recommended based on the results
of noninvasive screening tests (12).
Chromosome anomaly was seen in 3 of 17 cases (17%)
with amniocentesis both in karyotyping and in BACbased aCGH analysis due to advanced maternal age. In a
study conducted with 356 cases, Yüce et al. concluded that
1.2% of 158 cases with amniocentesis and chromosome
analysis due to advanced maternal age had a chromosome
anomaly (13). Api et al. found this rate to be 2.7% (14). We
consider that the high rate found in this study compared
with similar studies was due to the presence of additional
indications, such as high screening test results and fetal
anomalies.
Ultrasonography is an important constituent of the
noninvasive technique. Frequently observed ultrasound
findings in fetal chromosome findings can be listed
as increase in nuchal translucency, nonappearance of
nasal bone, choroid plexus cyst, and cystic hygroma.
Chromosome anomaly is only seen in 5% of cases with

abnormal ultrasound findings when considering all
ultrasound findings.
Amniocentesis was applied in 98 cases due to the high
screening test results and numerical and/or structural
chromosome anomaly was detected in 9 (10%) cases. Yüce
et al. recorded this rate as 3% in another study (13).
Cytogenetic analysis is primarily conducted in highrisk pregnancies. Nevertheless, a majority of patients
undergoing applied cytogenetic analysis have a normal
karyotype, but chromosomal alterations are observed
on a microscopic level in 5%–10% of cases (15). In this
study, this rate was found to be 9%, in conformity with the
findings of other studies.
Chromosome anomalies are responsible for different
complex phenotypes, such as mental retardation and
birth defects. While 80% of chromosome anomalies seen
in neonates are composed of trisomy 21, trisomy 18, and
trisomy 13 as autosomal aneuploidies, sex chromosome
anomalies such as Turner syndrome and Klinefelter
syndrome make up the remaining ones.
Down syndrome is the most commonly seen
chromosome anomaly in prenatal diagnosis. Trisomy 21
was observed in 4 cases in our study group. All of these
findings were specified with chromosome analysis and the
BAC array. Three of them were counted as the regular type
and one was a de novo Robertsonian translocation.
Cells were required to be grown in a cell culture in
order to raise the number of living cells in the amniotic
liquid sample for chromosome analysis. This procedure
lasted approximately 10–15 days. The anxiety levels of
the expectant mothers undergoing applied amniocentesis
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increased during this period. Moreover, time is of great
importance in the later gestational weeks, because
termination becomes harder in the case of a possible
anomaly if amniocentesis is applied in this period.
Therefore, techniques to get results more rapidly have been
developed. Quicker methods, requiring less endeavor, are
needed for microscopic karyotype analysis in order to
obtain results within the targeted period in prenatal tests.
The aCGH technology is available for use in prenatal
diagnosis in order to research structural chromosome
anomalies associated with genome-wide copy number
changes. The principle behind the aCGH technology
depends on the comparison of patients’ genomic DNAs
that have chromosomal deletion and duplications with
the same amounts from healthy samples. Imbalanced
chromosomal
anomalies
causing
simultaneously
aneuploidies of all chromosomes and alterations in the
copy number can be detected with the aCGH method in
a short time (16,17).
Amnion cell culturing both takes time and does not
always present successful results. The risk of failure in
culturing, encountered in all laboratories, increases the
anxiety of families, because another invasive procedure
may be needed in such a situation and the risks associated
with this intervention are repeated.
In our study, the culture success rate was 96.4% and
the success in getting final diagnostic results was 98.5%.
Similarly, Saatçi et al. reported the cell culture success rate
as 97% (18). FISH and BAC-based aCGH were applied in
cases that displayed no metaphase, and thus a difference
between these rates occurred and patients were informed
accordingly. Materials that were contaminated with
maternal blood had no procedures applied to them, due to
the nonconformity with molecular tests.
Mosaicism may be the main problem in the prenatal
diagnosis due to the hard-to-predict phenotypic effect
of karyotypes. There were 3 distinct cases with mosaic
karyotype in the study group. Two of them were numerical
and one of them was a structural anomaly. These mosaic
karyotypes could not be detected by aCGH. Detection of
mosaicism under 10% is a limitation of aCGH technology.
Balanced chromosome anomalies such as translocations
and inversions cannot be detected by aCGH. In prenatal
diagnosis, when balanced chromosome anomalies are
detected by chromosome analysis, parental chromosome
analysis is also necessary. If parents have normal
karyotypes, reporting can be more complex, because it
is reported that 6.1% of fetuses with translocations such
as de novo balanced chromosome anomaly carriers will
have abnormal phenotypes. In a study by Lee et al., de
novo balanced translocations were seen in 17 fetuses and
2 of them had submicroscopic deletions at translocation
breakpoints. These deletions were obtained only by aCGH.
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Balanced chromosome anomaly was detected in only one
case in our group. Inv (4) (p13q21) was observed in a
patient admitted with a high risk of trisomy 21. Inverted
chromosomes could not be identified by aCGH, as
expected. On the other hand, no submicroscopic deletions
or duplications were found in this case. The aCGH method
can be useful in cases of de novo balanced chromosome
anomaly (19,20).
Marker chromosomes are composed of chromosomes
of unknown origin. The phenotypic effect becomes
unpredictable if the origin of the increasing genetic
material is unknown, and aCGH may help in identification
of marker chromosomes depending on the euchromatin
participation and array resolution. Chromosome analysis
revealed a marker chromosome in one case when applied
to amniocentesis material. The origin of extra chromosome
parts was identified as belonging to the 14q11 area by
BAC aCGH. As a result of parental chromosome analysis,
t(7;14) was found in expectant mothers, and the part of
the chromosome appearing as a marker chromosome was
understood to be a derivative of chromosome 14.
The BAC aCGH displays genome-wide copy number
changes. The probability of encountering copy number
changes in such benign groups at, for example, an oligobased array platform, particularly with high resolution, is
higher than with a BAC-based array platform. Alterations
in copy number are classified as a pathological group with
known or unknown clinical effects and a benign group
with no or unknown clinical effects. Copy numbers both
in pathological and benign groups can be detected by
this method (16,17). No alteration of copy number with
suspicious phenotypic effect was observed in the study
group. It has been recorded that the detection of smallscale changes that is impossible by chromosome analysis,
and of changes with unknown prognosis and of changes
associated with no definite syndrome, results in possible
challenges in genetic counseling, especially in the prenatal
diagnosis period (21,22).
Array CGH has the advantage of being able to show
results in 3 days but it has limitations in detecting lowrate mosaicisms and balanced rearrangements such as
translocations and inversions. Our center has experience
with over 2500 aCGH samples to help to overcome
difficulties in bioinformatics analysis. However, it is
still a serious problem for us to interpret copy-number
variation data and unknown aberrations. BAC arrays
have lower resolutions than oligo-arrays but are capable of
detecting big rearrangements of over 100,000 base pairs,
since they have been produced by FISH probe sources.
Thus, BAC arrays are much more reliable in making
comments on diagnostic purposed studies.
Array CGH has a higher diagnostic capacity than
chromosome analysis for detecting chromosomal
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alterations in fetuses with normal karyotypes and
abnormal ultrasound findings. On the other hand, aCGH
is unable to screen balanced chromosomal alterations such
as triploidy and low-rate mosaicism, which can be detected
by chromosome analysis. However, both methods have
several limitations, and we think that using these methods

together gives the right information in routine prenatal
diagnosis. Unfortunately, aCGH platforms are still 10
times more expensive than cytogenetic studies. However,
the molecular diagnostic industry offers new options in
the next generation of sequencing, which will be available
at reasonable prices in the coming decades.
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